Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New cell therapy aims to make risky cancer transplants safer

NCT ID NCT03622788

Summary

This early-stage trial is testing whether adding specially treated immune cells, called 'veto cells,' can help patients with blood cancers or bone marrow failure after a stem cell transplant. The goal is to help the donor's cells grow in the patient's body without causing a dangerous immune reaction called graft-versus-host disease. The study involves 16 patients and is focused on finding the safest and most effective dose of these cells.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.